drugset / Trial / NCT05844956
A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)
NaSequentialOpen-labelTreatment
Summary
This study is designed to evaluate the safety, tolerability, pharmacokinetic profile, and antitumor efficacy of DZD8586 in participants with relapsed or refractory B-NHL.
Timeline
- Start
- 2022-06-01
- Primary completion
- 2024-02-29
- Completion
- 2024-02-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DZD8586 | Unknown | 10 mg | — |
| Subject | DZD8586 | Unknown | 25 mg | — |
| Subject | DZD8586 | Unknown | 50 mg | — |
| Subject | DZD8586 | Unknown | 100 mg | — |
| Subject | DZD8586 | Unknown | 150 mg | — |